Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation NATURE CLINICAL PRACTICE ONCOLOGY Pan, M., Santamaria, M., Wollman, D. B. 2007; 4 (10): 603-607

Abstract

A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema.Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis, bone scan, CT scan-guided biopsy, hematoxylin and eosin staining, EGFR mutational analysis, and chest X-ray.Stage IV non-small-cell lung cancer with brain metastasis.Oral erlotinib 150 mg daily for 10 months and ongoing, and whole-brain irradiation.

View details for DOI 10.1038/ncponc0931

View details for Web of Science ID 000249708800010

View details for PubMedID 17898810